Skip to main content

Table 3 Cox univariate analysis of PFS and OS.

From: Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

 

PFS

 

OS

 

HR*

95% CI

P value

 

HR

95% CI

P value

Sex

0.676

0.236–1.932

0.465

 

1.572

0.447–5.520

0.481

Age

0.943

0.360–2.469

0.904

 

0.699

0.265–1.842

0.469

Primary tumor sites

1.163

0.401–3.373

0.782

 

0.874

0.281–2.716

0.816

ECOG PS

0.885

0.285–2.752

0.833

 

1.080

0.306–3.816

0.905

Cancer grading

0.396

0.090–1.739

0.220

 

1.090

0.349–3.403

0.882

Lauren typing

0.297

0.095–0.926

0.036

 

0.529

0.169–1.656

0.274

Liver Metastasis

0.187

0.042–0.840

0.029

 

0.214

0.049–0.947

0.042

Metastasis site

0.430

0.161–1.151

0.093

 

0.595

0.220–1.606

0.306

Previous regimen

0.046

0-15955.418

0.636

 

2.688

0.340-21.246

0.348

Chemotherapy lines

1.123

0.318–3.968

0.858

 

1.213

0.345–4.268

0.764

  1. *HR: hazard ratio